The commissioner, Food and Drugs Administration (FDA) of Maharashtra, is learnt to have issued orders to stockists restricting them from marketing Disprin tablets in the state.
The order comes in the wake of reports that Reckitt Benckiser, the manufacturer, is marketing paracetamol and aspirin-based formulations under the same brand name.
Reckitt Benckiser used to manufacture an aspirin-based formulation under the brand name Disprin, but later discontinued the product and started marketing a paracetamol-based formulation under the same brand name.
Also Read
Subsequently, Reckitt Benckiser also introduced the original aspirin-based formulation under the same name, creating confusion in the market.
Legal experts have argued that marketing two entirely different formulations under the same brand name is against the prevailing laws of the land.
They pointed out that Reckitt Benckiser had launched Acetyl Salicylic Acid (Aspirin) under the brand name Disprin globally in 1948.
It was initially launched as a pain killer, but after researchers confirmed its utility in dilating blood vessels for heart patients, it was promoted as such.
The US Food and Drugs Administration department sought public opinion before approving it as a useful cardiovascular drug.
Further, research confirmed its utility in cerebro-vascular disorders and also in rheumatoid arthritis.
The US FDA thus approved the drug aspirin under the brand name Disprin with different labels having different colours and specifications for use in cardio-vascular, cerebro-vascular and rheumatoid diseases.
In India, the same company launched aspirin as Disprin, but recently changed the formulation to paracetamol.
The Maharashtra FDA has expressed surprise that the Drug Controller of neighbouring Karnataka, where the manufacturing unit of Reckitt Benckiser is based, is allowing the manufacture of different formulations under the same brand name.
Commissioner FDA, Maharashtra, Uttam Khobragade, confirmed that stockists have been asked to hold back stocks of Disprin until the matter is resolved.
He said he had also written to his counterparts in Karnataka and asked them to look into the issue.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
